Juan Carlos Garcia-Pagan

Summary

Country: Spain

Publications

  1. ncbi Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain
    J Hepatol 58:45-50. 2013
  2. ncbi Acute variceal bleeding
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Respir Crit Care Med 33:46-54. 2012
  3. ncbi Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 121:908-14. 2001
  4. ncbi [Covered transjugular intrahepatic portosystemic shunts]
    Juan Carlos Garcia-Pagan
    Laboratorio de Hemodinámica Hepática, Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, IDIBAPS, Hospital Clinic, Barcelona, Espana
    Gastroenterol Hepatol 29:647-51. 2006
  5. ncbi [Endoscopic ligature of esophageal varices in the treatment of portal hypertension]
    Juan Carlos Garcia-Pagan
    Laboratorio de Hemodinámica Hepática, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBABS, Ciberrehd Barcelona, Spain
    Rev Gastroenterol Mex 72:52-61. 2007
  6. ncbi Endoscopic band ligation in the treatment of portal hypertension
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Nat Clin Pract Gastroenterol Hepatol 2:526-35. 2005
  7. ncbi Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
    J C Garcia-Pagan
    Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 28:178-86. 2008
  8. ncbi TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit Hospital Clínic, IDIBAPS and Ciberehd, Barcelona, Spain
    Gastroenterology 135:808-15. 2008
  9. ncbi Early use of TIPS in patients with cirrhosis and variceal bleeding
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain
    N Engl J Med 362:2370-9. 2010
  10. ncbi Extrahepatic portal vein thrombosis
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Semin Liver Dis 28:282-92. 2008

Detail Information

Publications76

  1. ncbi Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain
    J Hepatol 58:45-50. 2013
    ..The aim of this study was to confirm these results in clinical practice in the same centers of the RCT study...
  2. ncbi Acute variceal bleeding
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Semin Respir Crit Care Med 33:46-54. 2012
    ..e., those Child B with active bleeding or Child C less than 14 points) markedly decreased rebleeding and improved survival...
  3. ncbi Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Gastroenterology 121:908-14. 2001
    ..The present study evaluates whether isosorbide-5-mononitrate (Is-MN) effectively prevents variceal bleeding in patients with contraindications or who could not tolerate beta-blockers...
  4. ncbi [Covered transjugular intrahepatic portosystemic shunts]
    Juan Carlos Garcia-Pagan
    Laboratorio de Hemodinámica Hepática, Unidad de Hepatologia, Institut de Malalties Digestives i Metaboliques, IDIBAPS, Hospital Clinic, Barcelona, Espana
    Gastroenterol Hepatol 29:647-51. 2006
    ..Therefore, e-PTFE-covered stents should be preferred over uncovered stents in the management of the complications of portal hypertension...
  5. ncbi [Endoscopic ligature of esophageal varices in the treatment of portal hypertension]
    Juan Carlos Garcia-Pagan
    Laboratorio de Hemodinámica Hepática, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBABS, Ciberrehd Barcelona, Spain
    Rev Gastroenterol Mex 72:52-61. 2007
    ..EBL in combination with vasoactive pharmacological treatment is the election treatment of acute hemorrhage by esophageal varices; nevertheless varices sclerotherapy can be made if the execution of EBL is technically difficult...
  6. ncbi Endoscopic band ligation in the treatment of portal hypertension
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Nat Clin Pract Gastroenterol Hepatol 2:526-35. 2005
    ..EBL, in combination with vasoactive drugs, is the recommended form of therapy for acute esophageal variceal bleeding; however, endoscopic injection sclerotherapy can be used in the acute setting if EBL is technically difficult...
  7. ncbi Review article: the modern management of portal hypertension--primary and secondary prophylaxis of variceal bleeding in cirrhotic patients
    J C Garcia-Pagan
    Liver Unit, Hepatic Hemodynamic Laboratory, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Aliment Pharmacol Ther 28:178-86. 2008
    ..Variceal bleeding is a life-threatening complication of liver cirrhosis with a high probability of recurrence. Treatment to prevent first bleeding or rebleeding is mandatory...
  8. ncbi TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit Hospital Clínic, IDIBAPS and Ciberehd, Barcelona, Spain
    Gastroenterology 135:808-15. 2008
    ..However, the influence of TIPS on patient survival and factors that predict the outcome of TIPS in BCS patients remain unknown...
  9. ncbi Early use of TIPS in patients with cirrhosis and variceal bleeding
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, University of Barcelona, Barcelona, Spain
    N Engl J Med 362:2370-9. 2010
    ..This study evaluated the earlier use of TIPS in such patients...
  10. ncbi Extrahepatic portal vein thrombosis
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, IDIBAPS and Ciberehd, Barcelona, Spain
    Semin Liver Dis 28:282-92. 2008
    ..Mortality among patients with PVT is low (5-year mortality rate of 5 to 10%) and is mainly related to associated diseases rather than to complications of portal hypertension...
  11. ncbi Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, University of Barcelona, Spain
    Gastroenterology 144:102-111.e1. 2013
    ..We looked for markers of the presence of CSPH and EVs in patients with cirrhosis...
  12. ncbi Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT
    Juan Carlos Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malaties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Hepatology 37:1260-6. 2003
    ..However, the long-term use of this combination drug therapy is safe and may be an alternative in clinical conditions associated with a greater risk of bleeding...
  13. ncbi Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Barcelona, Spain
    Hepatology 57:1172-81. 2013
    ..CONCLUSION: LPS administration induces intrahepatic endothelial dysfunction that might be prevented by simvastatin, suggesting that statins might have potential for liver protection during endotoxemia...
  14. ncbi Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial
    Andrea De Gottardi
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Clin Nutr 96:584-90. 2012
    ..In cirrhosis, hepatic endothelial dysfunction as a result of oxidative stress contributes to the postprandial increase in hepatic venous pressure gradient (HVPG)...
  15. ncbi Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Calle Villaroel 170, 08036 Barcelona, Spain
    J Hepatol 51:279-87. 2009
    ..However, two HVPG measurements are needed to evaluate response. This study was aimed at investigating the predictive role of acute HVPG response to i.v. propranolol for bleeding and survival...
  16. ncbi Insulin resistance in patients with cirrhosis and portal hypertension
    Eva Erice
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Am J Physiol Gastrointest Liver Physiol 302:G1458-65. 2012
    ..In nondiabetic patients with cirrhosis, HOMA-2 index is directly associated with the presence of CSPH and indirectly with varices, but does not allow either grading HVPG or predicting its response to propranolol...
  17. ncbi Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD
    Marcos Pasarín
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, CIBERrehd, University of Barcelona, Barcelona, Spain
    PLoS ONE 7:e32785. 2012
    ..In summary, we demonstrate in a rat model of the metabolic syndrome that shows features of NAFLD, that liver endothelial dysfunction occurs before the development of fibrosis or inflammation...
  18. ncbi Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension
    Vincenzo La Mura
    Hepatic Haemodynamic Laboratory, Liver Unit Hospital Clínic Institut de investigacions Biomèdiques August Pi i Suny IDIBAPS, University of Barcelona, Spain
    Gut 60:1133-8. 2011
    ..This study was aimed at exploring in patients with cirrhosis and portal hypertension the relation of these endothelial factors with systemic and hepatic haemodynamics and their possible clinical prognostic value...
  19. ncbi Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 43:98-103. 2005
    ..To determine whether this process is angiogenesis-dependent, we assessed the effects of SU5416, a specific inhibitor of VEGF receptor-2, in portal hypertensive rats...
  20. ncbi Nitric oxide and portal hypertension
    Juan González-Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Spain
    Metab Brain Dis 17:311-24. 2002
    ..Moreover, it cannot be ruled out that NO blockade may have a deleterious action on cirrhosis progression, which raises caution about their use in patients with cirrhosis...
  21. ncbi Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension
    Manuel Hernandez-Guerra
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    J Clin Gastroenterol 39:S131-7. 2005
    ..Some of these pharmacologic approaches have already been incorporated into clinical practice while others are still under investigation...
  22. ncbi TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy
    Antonia Perello
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, University of Barcelona, Barcelona, Catalunya, Spain
    Hepatology 35:132-9. 2002
    ..In conclusion, in patients with BCS uncontrolled with medical therapy, TIPS is a highly effective technique that is associated with long-term survival...
  23. ncbi Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death
    Andrea Ribeiro de Souza
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Clin Gastroenterol Hepatol 10:670-6; quiz e58. 2012
    ..However, little is known about their long-term outcomes...
  24. ncbi Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors
    Elba Llop
    Hepatic Hemodynamic Laboratory, Liver Unit, University of Barcelona, Spain
    J Hepatol 56:103-8. 2012
    ..Liver stiffness (LS) evaluation by transient elastography might non-invasively identify CSPH. We investigated the usefulness of LS predicting CSPH in patients with compensated cirrhosis and potentially resectable liver tumors...
  25. ncbi Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, Hospital Clinic, CIBERehd, Universitat de Barcelona, Barcelona, Spain
    Hepatology 46:1208-17. 2007
    ..Importantly, these findings also suggest that an extended antiangiogenic strategy (that is, targeting VEGF/endothelium and PDGF/pericytes) may be a novel approach to the treatment of portal hypertension...
  26. ncbi NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study
    Annalisa Berzigotti
    Hepatic Hemodynamics Laboratory, Hospital Clinic IDIBAPS, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 105:1094-101. 2010
    ..This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension...
  27. ncbi Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, , IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Am J Gastroenterol 101:506-12. 2006
    ..Reduction of HVPG also correlate with a reduced risk of SBP or bacteremia...
  28. ncbi Cardiovascular risk factors and systemic endothelial function in patients with cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Barcelona, Spain
    Am J Gastroenterol 108:75-82. 2013
    ..However, there is no prospective study evaluating the relationship between cardiovascular risk and systemic endothelial function in cirrhosis, which was investigated here...
  29. ncbi Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, , Institut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS, Universitat de Barcelona, Barcelona, Spain
    Hepatology 37:902-8. 2003
    ....
  30. ncbi Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study
    Vincenzo La Mura
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Hepatology 51:2108-16. 2010
    ..CONCLUSION: The excellent prognostic information provided by HVPG response to drug therapy is lost if HAPG response is considered. RAP should not be used for the calculation of portal pressure gradient in patients with cirrhosis...
  31. ncbi Sonography of Budd-Chiari syndrome
    Xavier Bargallo
    Department of Radiology, Hospital Clinic, C Villarroel, 170, Barcelona, Spain 08036
    AJR Am J Roentgenol 187:W33-41. 2006
    ..Half of the patients will develop regenerative nodules that can simulate hepatocellular carcinoma...
  32. ncbi PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome
    Manuel Hernandez-Guerra
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigaciones Biomèdiques August Pi i Sunyer, Barcelona, Spain
    Hepatology 40:1197-202. 2004
    ..PTFE-covered stents are preferable in patients with Budd-Chiari Syndrome...
  33. ncbi Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis
    Sebastian Raffa
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBERehd, Barcelona, Spain
    Clin Gastroenterol Hepatol 10:72-8. 2012
    ..We investigated the significance of these results...
  34. ncbi Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice
    Mercedes Fernandez
    Hepatic Hemodynamic Laboratory, Liver Unit, Insitut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Universityof Barcelona, Spain
    Gastroenterology 126:886-94. 2004
    ..The high relevance of these collateral vessels prompted us to investigate the mechanism underlying its formation in a murine model of portal hypertension...
  35. ncbi [Portal vein thrombosis]
    Susana Seijo-Ríos
    Laboratorio de Hemodinámica Hepática, Servicio de Hepatologia, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, CIBERehd, Barcelona, Espana
    Gastroenterol Hepatol 33:179-90. 2010
    ..To date, anticoagulation therapy is limited to patients in whom an underlying prothrombotic disorder has been demonstrated...
  36. ncbi Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension
    Jaume Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic IDIBAPS and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Spain
    J Hepatol 53:558-67. 2010
    ....
  37. ncbi Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Institut Malalties Digestives i Metabòliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Clin Gastroenterol Hepatol 6:1412-7. 2008
    ..Acute portal vein thrombosis (APVT) is a rare disorder that causes chronic portal hypertension if recanalization is not obtained. However, response to anticoagulation and long-term prognosis of APVT are not well-defined...
  38. ncbi Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Gastroenterology 136:1651-8. 2009
    ..This randomized controlled trial evaluated the effects of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG) and its safety in patients with cirrhosis and portal hypertension...
  39. ncbi Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera
    Alberto Alvarez-Larran
    Haematology Department, Institute of Haematology and Oncology, Hospital Clinic, IDIBAPS, University of Barcelona, Villaroel 170, 08036 Barcelona, Spain
    Br J Haematol 124:329-35. 2004
    ..05). These results support a role for neutrophils in BCS/PVT secondary to PV and indicate that neutrophil CD11b expression could be of use for PV screening in BCS/PVT patients...
  40. ncbi Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis
    Rafael Bañares
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital General Universitario Gregorio Maranon, Universidad Complutense, Madrid, Spain
    Hepatology 36:1367-73. 2002
    ..However, its clinical applicability may be limited by its systemic hypotensive effects. Further trials are needed to confirm the therapeutic potential of carvedilol...
  41. ncbi Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Barcelona, Spain
    J Hepatol 52:846-53. 2010
    ..We aimed to examine the diagnostic value of these methods in patients with a suspicion but not a definite diagnosis of cirrhosis...
  42. ncbi Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis
    Juan Turnes
    Hepatic Hemodynamic Laboratory, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, IDIBAPS, Barcelona, Spain
    Hepatology 43:34-41. 2006
    ..However, HVPG reduction cannot be predicted from polymorphism analysis. Patients with the Gly16-Glu/Gln27 haplotypes may benefit from the association of hepatic vasodilators to propranolol therapy...
  43. ncbi Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis
    Pablo Bellot
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 52:2044-52. 2010
    ..Conclusion: Presence of bacterial DNA, a marker of bacterial translocation, is associated with aggravation of peripheral vasodilation and with worsening of intrahepatic endothelial dysfunction...
  44. ncbi Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis
    Annalisa Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, Spain
    J Hepatol 55:307-14. 2011
    ..This study evaluated the feasibility of contrast-enhanced ultrasonographic (CEUS) estimations of regional hepatic perfusion in patients with cirrhosis, and its correlation with clinical and hemodynamic parameters...
  45. ncbi Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats
    Bernhard Angermayr
    Liver Unit, Hepatic Hemodynamic Laboratory, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 44:1033-9. 2006
    ..In this study, we determined the role of heme oxygenase-1 on oxidative stress, inflammation, angiogenesis, and splanchnic hemodynamics in rats with portal hypertension induced by partial portal vein ligation...
  46. ncbi Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: a case-control study
    Filippo Schepis
    Hepatic Hemodynamic Laboratory and Liver Transplantation Section, Barcelona, Spain
    Liver Transpl 19:450-6. 2013
    ..In contrast to nontransplant patients, propranolol increases the systemic vascular resistance and arterial pressure in transplant patients with cirrhosis and attenuates the fall in CI...
  47. ncbi Portal cholangiopathy: radiological classification and natural history
    Elba Llop
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona 08036, Spain
    Gut 60:853-60. 2011
    ..This study investigated the relationship between cholangiographic abnormalities and clinical symptoms and their evolution over time...
  48. ncbi Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis
    María Gabriela Delgado
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clínic Institut de Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, University of Barcelona, Barcelona, Spain
    Clin Gastroenterol Hepatol 10:776-83. 2012
    ..We evaluated this therapy in a large series of patients with cirrhosis and non-neoplastic PVT...
  49. ncbi The management of portal hypertension: rational basis, available treatments and future options
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Hospital Clinic, C Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 48:S68-92. 2008
    ....
  50. ncbi Prevention of variceal rebleeding
    Jaume Bosch
    Hepatic Haemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives, Hospital Clinic, IDIBAPS, University of Barcelona, 08036, Barcelona, Spain
    Lancet 361:952-4. 2003
    ..The role of HVPG monitoring as a guide to identifying patients requiring further treatment needs to be further evaluated. Trials to determine the best treatment for patients who do not respond to drug therapies are also required...
  51. ncbi Acute and long-term effects of inhaled iloprost in portopulmonary hypertension
    Maria Teresa Melgosa
    Department of Pulmonary Medicine, University of Barcelona, Barcelona, Spain
    Liver Transpl 16:348-56. 2010
    ..Its long-term use may provide sustained improvements in symptoms and exercise tolerance in some patients with PoPH. A randomized, controlled trial is warranted to establish its clinical role in this serious condition...
  52. ncbi A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients
    Puneeta Tandon
    Hospital Clinic, University of Barcelona, Barcelona, Spain
    Am J Gastroenterol 105:1917-21. 2010
    ..We aimed to evaluate the dosing and tolerance of BBs achievable in a specialized, nurse-run BB titration clinic with non-trial participants...
  53. ncbi Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy
    Beatriz Minguez
    Servei de Medicina Interna Hepatologia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Hepatology 43:707-14. 2006
    ..These disturbances, which include signs of increase in brain water and a compensatory osmotic response (decrease in brain myo-inositol), appear to be secondary to brain exposure to ammonia induced by portal-systemic shunting...
  54. ncbi Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation
    José A Carrión
    Liver Unit, Institut de Malalties Digestives, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, CIBERehd, Barcelona, Spain
    Gastroenterology 138:147-58.e1. 2010
    ..This study evaluated whether serum fibrosis markers can predict hepatitis C recurrence during the first year after liver transplantation...
  55. ncbi Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis
    Puneeta Tandon
    Hospital Clinic, Liver Unit, Barcelona, Spain
    J Hepatol 53:273-82. 2010
    ..We evaluated the efficacy and safety of RAAS inhibitors in hepatic venous pressure gradient (HVPG) reduction...
  56. ncbi Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy
    Pik Eu Chang
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Am J Gastroenterol 104:1707-14. 2009
    ..We describe for the first time the hepatic and systemic hemodynamic profile, liver stiffness, and histological features of eight patients with HIV-related IPH...
  57. ncbi Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension
    Andrea De Gottardi
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    J Cell Mol Med 16:2017-21. 2012
    ..We did not detect mutations or rearrangements in the coding region of the BMPR2 gene in our patients with IPH. These findings suggest that, in contrast to IPAH, mutations in BMPR2 are not involved in the pathogenesis of IPH...
  58. ncbi Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension
    Susana Seijo
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer IDIBAPS, University of Barcelona, Spain
    Dig Liver Dis 44:855-60. 2012
    ..This study evaluates specific findings at hepatic vein catheterisation or liver stiffness in idiopathic portal hypertension...
  59. ncbi Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis
    Javier Fernandez
    Liver Unit, IMD, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain
    J Hepatol 41:384-90. 2004
    ..Albumin administration prevents renal failure and improves survival in spontaneous bacterial peritonitis. This study characterizes the mechanisms of action of albumin in this condition...
  60. ncbi Sonography of the caudate vein: value in diagnosing Budd-Chiari syndrome
    Xavier Bargallo
    Department of Radiology, Hospital Clinic, C Villarroel, 170, Barcelona 08036, Spain
    AJR Am J Roentgenol 181:1641-5. 2003
    ..The aim of this study was to evaluate the usefulness of sonography in measuring the caudate vein and lobe when diagnosing Budd-Chiari syndrome...
  61. ncbi 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes
    Mariona Graupera
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut Malaties Digestives Hospital Clinic, University of Barcelona, Barcelona, Spain
    Gastroenterology 122:387-93. 2002
    ..The aim of this study was to investigate the role of 5-lipoxygenase-derived eicosanoids regulating intrahepatic vascular tone in control and CCl4-induced cirrhotic rat livers...
  62. ncbi Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial
    J C Garcia-Pagan
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut de Malalties Digestives i Metaboliques, Hospital Clinic, Institut de Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Gut 58:1144-50. 2009
    ..The present study was aimed at evaluating this issue in a multicentre randomised controlled trial (RCT) and to correlate changes in hepatic venous pressure gradient (HVPG) during treatment with clinical outcomes..
  63. ncbi Refractory acute variceal bleeding: what to do next?
    Mario D'Amico
    Hospital Clinic, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Barcelona, Spain
    Clin Liver Dis 14:297-305. 2010
    ....
  64. ncbi The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins
    Giusi Marrone
    Hepatic Hemodynamic Laboratory, August Pi i Sunyer Institute for Biomedical Research IDIBAPS, Hospital Clinic de Barcelona, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Barcelona, Spain
    J Hepatol 58:98-103. 2013
    ..The present study aimed at characterizing whether KLF2 mediates statins-derived hepatic protection...
  65. ncbi Animal models of portal hypertension
    Juan G Abraldes
    Liver Unit, Hospital Clinic, Villarroel 170, University of Barcelona 08036, Spain
    World J Gastroenterol 12:6577-84. 2006
    ..The criteria for choosing a particular model, depending on the specific objectives of the study, are also discussed...
  66. ncbi Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers
    Lucia Russo
    Hepatic Hemodynamic Lab, Liver Unit, IMDiM, Hospital Clinic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Barcelona, Spain
    Hepatology 55:921-30. 2012
    ..CONCLUSION: Our results provide a rationale to evaluate the beneficial effects of a vasoprotective preservation solution on human liver procurement for transplantation...
  67. ncbi Portal hypertension and gastrointestinal bleeding
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Institut d Investigacions Biomediques August Pi i Sunyer, University of Barcelona, Spain
    Semin Liver Dis 28:3-25. 2008
    ..This article reviews the rationale for the management of portal hypertension and the current recommendations for the prevention and treatment of variceal bleeding...
  68. ncbi The clinical use of HVPG measurements in chronic liver disease
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic and CIBEREHD, University of Barcelona, Barcelona, Spain
    Nat Rev Gastroenterol Hepatol 6:573-82. 2009
    ..Responders have a markedly decreased risk of bleeding (or rebleeding), ascites, and spontaneous bacterial peritonitis, which results in improved survival...
  69. ncbi Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis
    Annalisa Berzigotti
    Liver Unit, Hospital Clinic, Barcelona, Spain CIBERehd, Barcelona, Spain
    Hepatology 54:555-61. 2011
    ..Weight reduction may be a valuable therapeutic measure in this patient population...
  70. ncbi Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial
    Jaime Bosch
    Hepatic Hemodynamic Laboratory, Hospital Clinic and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, University of Barcelona, Spain
    Hepatology 47:1604-14. 2008
    ..Adverse events were comparable across groups...
  71. ncbi NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats
    Bernhard Angermayr
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Institut d Investigacions, Biomediques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
    Gut 56:560-4. 2007
    ..Therefore, it could be possible that activated NAD(P)H oxidases modulate angiogenesis in portal hypertension...
  72. ncbi Prevention of recurrent variceal bleeding
    A Berzigotti
    Hepatic Hemodynamic Laboratory, Liver Unit, IMD, Hospital Clinic, IDIBAPS and Ciberehd, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Dig Liver Dis 40:337-42. 2008
    ..Therefore, in this situation, transjugular intrahepatic porto-systemic shunt using polytetrafluoroethylene stents should be the treatment of choice...
  73. ncbi Primary prophylaxis of esophageal variceal bleeding in cirrhosis
    P Bellot
    Hepatic Hemodynamic Laboratory and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas Ciberehd, Liver Unit, IMD, Hospital Clinic, IDIBAPS, University of Barcelona, C Villarroel 170, 08036 Barcelona, Spain
    Gastroenterol Clin Biol 32:532-40. 2008
    ..There is no evidence to support using beta-blockers with nitrates or spironolactone. In patients with contraindication or intolerance to beta-blockers, endoscopic band ligations are indicated...
  74. ncbi Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats
    Juan G Abraldes
    Hepatic Hemodynamic Laboratory, Liver Unit, IMDiM, Hospital Clinic, CIBERehd, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 46:1040-6. 2007
    ..Statins improve endothelial dysfunction in peripheral vasculature. This study was designed to characterize the hemodynamic and molecular effects of statins in cirrhotic rats...
  75. ncbi Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension
    B Laviña
    Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clinic, Barcelona, Spain
    Gut 58:118-25. 2009
    ..NO scavenging by superoxide (O(2)(-)) further contributes to a reduction of NO bioavailability in cirrhotic livers...
  76. ncbi Large spontaneous splenorenal shunt as a cause of chronic hepatic encephalopathy
    José A Carrión
    Liver Unit, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    J Hepatol 40:868. 2004